Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Protocol No
NRG-GU012-SAMURAI
Principal Investigator
William Hall
Phase
II
Summary
This study is being done to answer the following question: Can we increase the time without your renal cell cancer getting worse or requiring surgery by adding radiation therapy to the usual immune therapy? We are doing this study because we want to find out if this approach is better than the usual approach for your renal cell cancer. The usual approach is defined as care most people get for renal cell cancer.
Description
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL